Sekar Kathiresan (Verve)

'Bluest of blue-chip in­vestors' pump $94M in­to Sekar Kathire­san's quest to bring CRISPR to the heart

Go­ing in­to his first JP Mor­gan con­fer­ence, Sekar Kathire­san had some ma­jor news to share. His am­bi­tious car­dio­vas­cu­lar-fo­cused start­up, Verve Ther­a­peu­tics, had des­ig­nat­ed the PC­SK9 base ed­i­tor as its lead pro­gram, homed in on se­vere het­erozy­gous fa­mil­ial hy­per­c­ho­les­terolemia as the first in­di­ca­tion, and re­leased an­i­mal da­ta sug­gest­ing the in vi­vo ed­its to the mon­key liv­ers last up to six months. For a com­pa­ny that had just been in the pub­lic for less than a year, “it was won­der­ful.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.